Abstract
Hidradenitis suppurativa (HS) is a chronic, multifactorial skin disease predominantly affecting apocrine gland-rich areas. Historically considered bacterial due to its suppurative nature, HS is now recognized as an immune-mediated condition driven by dysregulated inflammation rather than primary infection.1 Its pathogenesis involves a complex interplay of follicular occlusion, innate and adaptive immune dysregulation and environmental or genetic factors, resulting in recurrent painful nodules, abscesses and sinus tract formation.1 Despite this evolving understanding, first-line therapy in milder stages remains largely antibiotic-based. However, antibiotics cannot be used long-term due to potential adverse effects and the risk of bacterial resistance. Recent therapeutic advances, notably anti-TNF-α agents and IL-17 inhibitors, have demonstrated substantial efficacy in controlling disease activity and reducing flares, particularly in patients with moderate-to-severe HS.2, 3 These agents target key inflammatory pathways, addressing the underlying immune dysregulation rather than only managing secondary bacterial colonization.1 A recent survey by Nikolakis et al.,4 published in JEADV, assessed prescription patterns, unmet needs and expert opinions regarding systemic therapies for HS among 55 European specialists, most affiliated with the European Hidradenitis Suppurativa Foundation (EHSF). The findings highlighted a persistent gap between clinical practice, regulatory mandates and emerging evidence. Although clinicians generally follow licensing rules requiring a 10–12-week course of antibiotics, 81% reported prescribing antibiotics even when response was unlikely, and more than half observed patient flares during therapy. These results suggest that antibiotic treatment often fails to control disease activity, potentially delaying access to more effective options. The survey also revealed strong support for early biologic use in early-stage ‘Hurley I’ disease: 79% of participants favoured short-term biologic therapy over antibiotics, with durations ranging from 12 to 24 weeks, reflecting a trend towards targeted, time-limited courses tailored to individual patient needs. Current guidelines approve biologics (e.g., adalimumab, secukinumab and bimekizumab) as first-line therapies only for moderate-to-severe HS (Hurley II–III).5 In mild forms, it is therefore essential to assess lesion characteristics, flare frequency and relevant comorbidities to identify patients at high risk of progression who may benefit from early initiation of biologic therapy. Notably, 95% of participants agreed that clearer guidance on first-line biologic use would be valuable in clinical practice.4 Nonetheless, further studies are needed to validate these risk criteria, define optimal timing for intervention and determine the most effective treatment strategies for early-stage HS. The HS community therefore stands at a pivotal moment: the shift towards recognizing HS as an immune-driven disease necessitates a re-evaluation of first-line treatment paradigms. Evidence from clinical practice suggests that early, targeted biologic therapy is both feasible and desirable. Even so, antibiotics may serve as a temporary treatment to manage infections and control symptoms while patients undergo the necessary screening tests prior to initiating biologic therapy. In conclusion, collaboration among clinicians, researchers and regulatory bodies is essential to develop evidence-based guidelines that support timely intervention, optimize outcomes, and improve quality of life for patients living with this challenging disease. Importantly, because biologic therapies can target dysregulated innate immunity from the earliest stages of HS, their timely use may help prevent irreversible tissue damage and long-term disease progression. Developing consensus-based criteria for early biologic intervention could therefore help reconcile regulatory frameworks with emerging evidence, ultimately enhancing patient care and reducing healthcare costs. The authors have nothing to report. None for the authors to disclose. Not applicable. Not applicable. Data sharing is not applicable to this article as no new data were created or analysed in this study.